SRDX Stock - Surmodics, Inc.
Unlock GoAI Insights for SRDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $126.08M | $132.58M | $99.95M | $105.14M | $94.86M |
| Gross Profit | $93.05M | $61.02M | $29.00M | $41.23M | $29.36M |
| Gross Margin | 73.8% | 46.0% | 29.0% | 39.2% | 30.9% |
| Operating Income | $-5,645,000 | $5.15M | $-22,097,000 | $6.70M | $-1,251,000 |
| Net Income | $-11,542,000 | $-1,536,000 | $-27,274,000 | $4.24M | $1.12M |
| Net Margin | -9.2% | -1.2% | -27.3% | 4.0% | 1.2% |
| EPS | $-0.82 | $-0.11 | $-1.96 | $0.31 | $0.08 |
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 14th 2025 | Barrington Research | Downgrade | Underperform | - |
| March 7th 2025 | Lake Street | Upgrade | Buy | $43 |
| June 13th 2023 | Needham | Upgrade | Buy | $36 |
| February 13th 2023 | Needham | Downgrade | Hold | - |
Earnings History & Surprises
SRDXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q4 2025 | Dec 3, 2025 | $-0.18 | — | — | — |
Q4 2025 | Nov 26, 2025 | $-0.19 | — | — | — |
Q3 2025 | Aug 8, 2025 | $-0.21 | $0.06 | +128.6% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $-0.06 | $-0.13 | -116.7% | ✗ MISS |
Q1 2025 | Jan 30, 2025 | $-0.12 | $-0.04 | +66.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.27 | $-0.13 | +51.9% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-0.31 | $-0.27 | +12.9% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $-0.36 | $0.07 | +119.4% | ✓ BEAT |
Q1 2024 | Feb 1, 2024 | $-0.30 | $-0.06 | +81.4% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.19 | $0.53 | +178.9% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $0.05 | $0.52 | +940.0% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $-0.49 | $-0.40 | +18.4% | ✓ BEAT |
Q1 2023 | Feb 6, 2023 | $-0.64 | $-0.50 | +21.9% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.38 | $-0.26 | +31.6% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $-0.39 | $-0.34 | +12.8% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $-0.32 | $-0.22 | +31.3% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $-0.36 | $-0.13 | +63.9% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.25 | $-0.10 | +60.0% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.11 | $-0.17 | -54.5% | ✗ MISS |
Latest News
Surmodics gains as FTC won't appeal denial of GTCR deal injunction
📈 PositiveSurmodics Announces FTC Does Not Intend To Appeal Denial Of Injunction, And Surmodics Expects To Close The Acquisition Promptly
📈 PositiveBarrington Research Downgrades Surmodics to Underperform
📉 NegativeSurmodics shares are trading higher after a US court reportedly denied the Federal Trade Commission's bid to block GTCR's acquisition of the company.
📈 PositiveSurmodics surges after court denies injunction to block sale to GTCR
📈 PositiveTrading Halt: Halt status updated at 6:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralU.S. Court Denies U.S. Federal Trade Commission's Bid To Block GTCR's Acquisition Of Surmodics
📈 PositiveTrading Halt: Halted at 2:45:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralSurmodics Reports Strong PROWL Registry Results Showing 91.7% Procedural Success And 0.6% Adverse Events For Pounce Thrombectomy In Real-World Limb Ischemia
📈 PositiveSurmodics Doctors to Share Updated Real-World Results for Pounce Clot Removal Platform in Las Vegas
📈 PositiveSurmodics Prowl Registry Study Data Demonstrates High Procedural Success Across Sexes Throughout 160 Acute, Subacute, And Chronic Thrombotic Limb Ischemia Patients
📈 PositiveSurmodics To Present PROWL Registry Sex-Specific Data From Analysis Of 160 Participants At TCT Symposium On Oct. 28
➖ NeutralSurmodics falls as parties, FTC ask for extension of briefing schedule
📉 NegativeFrequently Asked Questions about SRDX
What is SRDX's current stock price?
What is the analyst price target for SRDX?
What sector is Surmodics, Inc. in?
What is SRDX's market cap?
Does SRDX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SRDX for comparison